This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split
Psychedelics biotech firm Clearmind Medicine Inc.
Cybin Shares Q2 Financial & Business Results, Focus On Licensing Deals For Preclinical Assets
Cybin Inc. (NYSE: CYBN) reported its unaudited financial results for its second quarter ended September 30, 2022, and provided business highlights for the period.
eXp Realty Picks New Chief Strategy Officer
eXp World Holdings Inc (NASDAQ:EXPI) core subsidiary eXp Realty has appointed Leo Pareja as Chief Strategy Officer. In the role,…
Foxo Technologies, Effective November 14, 2022, Jon Sabes Has Been Terminated As CEO And Chairman Of Board Of Company; Appointed Tyler Danielson, As Interim CEO And Bret Barnes As Chairman Of The Board
FOXO Technologies Inc. (NYSEAM:FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science,
Roper Names Company Veteran Jason Conley As CFO, Succeeding Rob Crisci
Roper Technologies, Inc (NYSE:ROP) Vice President and Chief Accounting Officer Jason Conley will succeed Rob Crisci as Executive Vice…
Mydecine’s Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business highlights for the three and nine months ended September 30, 2022.
Holley Reports Mixed Q3 Earnings
Holley Inc (NYSE:HLLY) reported a third-quarter FY22 sales decline of 3.1% year-on-year to $154.78 million, beating the consensus of $152.77 million.…
Rigetti Computing Files Extension For Q3 Financial Results; Co. Appoints Rick Danis As Interim CEO
Rigetti Computing, Inc. (NASDAQ:RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that it has filed for an extension for the filing of its
Reunion Neuroscience Presents Q2 2023 Financial Results & Pipeline Update
Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.
Filament Health Shares Q3 2022 Results, On Road To Becoming Industry’s Natural Psilocybin Supplier
Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022.